about
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityBoosting antibody developability through rational sequence optimization.Antibodies to watch in 2015Progress and challenges in predicting protein interfacesOpening the door to innovationPepsin-Containing Membranes for Controlled Monoclonal Antibody Digestion Prior to Mass Spectrometry Analysis.The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo.Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.Characterization and screening of IgG binding to the neonatal Fc receptor.Effect of formulation on the stability and aerosol performance of a nebulized antibodyImmunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.Generation and analysis of the improved human HAL9/10 antibody phage display libraries.Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class.A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.Antibodies to watch in 2017Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.Phase II drugs that are currently in development for the treatment of cachexia.Natural product and natural product derived drugs in clinical trials.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Nebulization as a delivery method for mAbs in respiratory diseases.Achieving incompatible transplantation through desensitization: current perspectives and future directions.The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics.Phage display-derived human antibodies in clinical development and therapyAlternative reagents to antibodies in imaging applications.Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.Insights into the molecular basis of a bispecific antibody's target selectivity.Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CAAZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use--improves psoriasis in a human xenograft transplantation model.Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma.Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis.The Immunogenetics of Psoriasis and Implications for Drug Repositioning.Antibodies to watch in 2018.A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective.
P2860
Q26862220-6CAAA882-91AC-40A8-AD11-87DA76B87BD3Q27311159-D78227C6-16BA-42FB-91EE-D012F2C68053Q28253501-E37A204F-D868-4514-A396-1F3B6AD5561EQ28602320-2406B28B-E81B-4FC2-80CF-A66B1F21EAE7Q28655591-6CA36639-9C30-4137-8A67-FF70FFD864C8Q30278544-BB522A21-06CB-4293-80E9-592841D76C40Q33922498-CF4C133E-C2F6-4282-8D36-AF15C22246EFQ34101828-0ECA3125-9E2C-4BB3-A883-9DD20A2CB3F4Q35163945-161CA0DA-7E5E-472D-ADA4-B5A660280244Q35526961-DD7DED15-D8FB-4480-A826-995DD583F72AQ35597598-3BFD024A-B0B9-4095-A7B6-7858A02D1800Q35608279-40B2F28E-FCE9-4B0B-B80F-5F40C2A0F4FAQ35864213-C42A76DF-57FD-4C38-8A60-BE938DAF3506Q36211427-5076AC73-3B96-403A-A3BA-39004797D523Q36212815-1CFF7266-BA45-4D24-A89F-DE4148025D0CQ36214988-5BC79B93-1941-4CF5-BDED-02877DC41BA6Q37631319-B6E96741-0850-42CA-81C4-0D1030B87FF7Q37698918-0661FE32-0A5B-4EFD-AF2E-FAD8B4EB9B70Q38208275-1EA024F5-F50C-420F-A42D-A0359A612565Q38212929-CB8BD585-26F0-4D60-9819-EBF7C93C1149Q38230884-3EC6A0F7-8D44-4188-A1BF-BC88D512A4AAQ38233278-CFE312D8-FF54-4B29-8CC6-EA4E4EA3E7E9Q38247457-99B2A0E8-4800-40F4-8DAC-2F7D53F1055DQ38289992-69E95C74-283B-4A21-B28C-D066AA2ED789Q38306677-FB138335-D90D-4653-BE09-6063692E26E7Q38445336-8E026104-D246-4296-9580-5AC0DB800934Q40601021-8E4EDC01-91CA-4C6F-B504-D137B20CD2BEQ40724867-E6ED4077-4065-4ECB-A22A-5FC7E7CE833FQ41416393-DB53A574-5FEC-4893-8A9F-B850FFB3792EQ41579389-D0A2317D-A22C-4EA9-9831-D423934678C8Q41596017-3FAD48B9-49DA-456A-9B86-37FBA30F38B6Q41946862-A88B2648-6D64-497A-AFE1-59C007ACD1E8Q42173120-6828E72A-27E1-47C6-BE4F-AC557ED3F8FAQ42557137-4A95F4AE-3309-4472-97C6-8F52232BA7FFQ45795416-94BAECD5-2390-4F0B-A155-86B7E78BF1DCQ47722523-5A42249B-2F11-4068-861B-46631BF03634Q48056780-414BCFA9-BEAA-4654-B4E5-3F53A61A5BC3Q48324692-B0D28F5F-9068-464D-B419-D6F731CB2A32Q50120289-D1605313-FCFE-4F8E-B0DD-BDA14F34DBE9Q50192844-2A4D73ED-2EB2-450D-98F5-0014A26A1DD1
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antibodies to watch in 2014.
@en
Antibodies to watch in 2014.
@nl
type
label
Antibodies to watch in 2014.
@en
Antibodies to watch in 2014.
@nl
prefLabel
Antibodies to watch in 2014.
@en
Antibodies to watch in 2014.
@nl
P2860
P356
P1476
Antibodies to watch in 2014.
@en
P2093
Janice M Reichert
P2860
P356
10.4161/MABS.27333
P577
2013-11-25T00:00:00Z